🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Muscular Dystrophies

Multiparametric Ultrafast Ultrasound Biomarkers for Duchenne and Becker Muscular Dystrophies NCT07378553n/a1 site📍 Nantes Nantes University Hospital Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD) NCT07086521Phase 11 site📍 Palo Alto Restem, LLC. · Tests: ULSC, Placebo Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting NCT07542314Phase 41 site📍 Houston Sarepta Therapeutics, Inc. · Tests: ELEVIDYS, Sirolimus, Glucocorticoids, Antibiotics Amino Acids and Exercise in FSHD NCT07543016NA1 site📍 Voghera University of Pavia · Tests: Essential Amino Acids Supplementation intervention, Exercise, Diet, Placebo Control Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds) NCT06847282n/a7 sites📍 Palo Alto📍 Iowa City📍 Kansas City University of Kansas Medical Center Registry for Duchenne and Becker Muscular Dystrophy NCT07402122n/a30 sites📍 Graz📍 Innsbruck📍 Linz Dr. Andreas Ziegler A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) NCT06138639Phase 1, Phase 215 sites📍 Little Rock📍 Los Angeles📍 Sacramento Solid Biosciences Inc. · Tests: SGT-003 Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders NCT05726591NA1 site📍 Bethesda National Institutes of Health Clinical Center (CC) · Tests: EA-KAFO A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort NCT04626674Phase 112 sites📍 Little Rock📍 La Jolla📍 Los Angeles Sarepta Therapeutics, Inc. · Tests: delandistrogene moxeparvovec Clenbuterol to Target DUX4 in FSHD NCT06721299Phase 13 sites📍 Kansas City📍 Rochester📍 Seattle Jeffrey Statland · Tests: Clenbuterol A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1 NCT06844214Phase 1, Phase 210 sites📍 Gainesville📍 Tampa📍 New York Sanofi · Tests: SAR446268 Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology NCT07136844NA1 site📍 Liège Centre Hospitalier Universitaire de Liege · Tests: Syde, Dynamometric measurements of muscle strength, The 6-minute walk test (6MWT), The 10-meter test (10MWT), The 4 sta… Rare Disease Registry Database for Movement Disorders in Southern Anhui Province NCT07838883n/a1 site📍 Wuhu First Affiliated Hospital of Wannan Medical College Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders NCT06147414n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Blood sample Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old NCT06769633Phase 29 sites📍 Brussels📍 Milan📍 Roma Italfarmaco · Tests: Givinostat Hydrochloride, Givinostat Hydrochloride - Cohort 2 Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy NCT06503367n/a14 sites📍 Los Angeles📍 Stanford📍 Chicago Nationwide Children's Hospital Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy NCT05016908n/a2 sites📍 Boston📍 Boston Massachusetts General Hospital DMCRN-02-001: Assessing Pediatric Endpoints in DM1 NCT05224778n/a5 sites📍 Los Angeles📍 Fairway📍 Rochester Virginia Commonwealth University Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT) NCT07521930NA1 site📍 Baltimore Johns Hopkins University · Tests: INTENT Neural Interface System Respiratory Progression in Adults With Duchenne Muscular Dystrophy. NCT07879989n/a13 sites📍 Bologna📍 Bosisio Parini📍 Calambrone Istituto Giannina Gaslini Inherited Retinal Degenerative Disease Registry NCT02435940n/a1 site📍 Columbia Foundation Fighting Blindness Invasive Home Ventilation in Denmark NCT07467187n/a1 site📍 Copenhagen Copenhagen University Hospital, Rigshospitalet Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy NCT07704099Phase 22 sites📍 Auckland📍 Christchurch Keros Therapeutics, Inc. · Tests: KER-065 Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 NCT07486934Phase 343 sites📍 La Jolla📍 Los Angeles📍 Palo Alto Dyne Therapeutics · Tests: zeleciment basivarsen (DYNE-101), Placebo Biomarker Development for Muscular Dystrophies NCT05019625n/a5 sites📍 Boston📍 Boston📍 Boston Massachusetts General Hospital Observatoire Des Patients Atteints de Laminopathies et Emerinopathies (Observatory for PAtients With Laminopathies and Emerinopathies) NCT03058185n/a29 sites📍 Angers📍 Strasbourg📍 Marseille Pitié-Salpêtrière Hospital Natural History of Oculo-Pharyngeal Muscular Dystrophy (OPMD) - Israel National OPMD Registry NCT07146256n/a1 site📍 Ramat Gan Sheba Medical Center · Tests: Non-interventional observational study Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers NCT07321977NA1 site📍 Paris Institut de Myologie, France · Tests: Gait analysis via video capture PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD) NCT07429240Phase 1, Phase 22 sites📍 Little Rock📍 St Louis Precision BioSciences, Inc. · Tests: PBGENE-DMD (IV) Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation NCT06813443n/a3 sites📍 Bologna📍 Roma📍 Florence IRCCS Azienda Ospedaliero-Universitaria di Bologna
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy